Next-Generation Probiotics for Inflammatory Bowel Disease.
bioengineering
biosensors
biotherapeutics
inflammatory bowel disease
probiotics
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
13 May 2022
13 May 2022
Historique:
received:
27
04
2022
revised:
10
05
2022
accepted:
11
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Engineered probiotics represent a cutting-edge therapy in intestinal inflammatory disease (IBD). Genetically modified bacteria have provided a new strategy to release therapeutically operative molecules in the intestine and have grown into promising new therapies for IBD. Current IBD treatments, such as corticosteroids and immunosuppressants, are associated with relevant side effects and a significant proportion of patients are dependent on these therapies, thus exposing them to the risk of relevant long-term side effects. Discovering new and effective therapeutic strategies is a worldwide goal in this research field and engineered probiotics could potentially provide a viable solution. This review aims at describing the proceeding of bacterial engineering and how genetically modified probiotics may represent a promising new biotechnological approach in IBD treatment.
Identifiants
pubmed: 35628274
pii: ijms23105466
doi: 10.3390/ijms23105466
pmc: PMC9141965
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Proc Natl Acad Sci U S A. 1989 Mar;86(5):1578-82
pubmed: 2466294
J Cell Mol Med. 2018 Feb;22(2):706-715
pubmed: 28990365
ACS Nano. 2021 Apr 27;15(4):7040-7052
pubmed: 33819424
Adv Exp Med Biol. 2010;681:107-16
pubmed: 21222263
Microorganisms. 2021 Mar 17;9(3):
pubmed: 33802777
Gastroenterology. 2004 May;126(6):1620-33
pubmed: 15168372
Mucosal Immunol. 2010 Jan;3(1):49-56
pubmed: 19794409
Front Bioeng Biotechnol. 2020 Mar 31;8:265
pubmed: 32296696
Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506-14
pubmed: 24912386
Front Nutr. 2022 Feb 22;9:821900
pubmed: 35295917
Gastroenterology. 2014 Jan;146(1):210-221.e13
pubmed: 24120477
Appl Microbiol Biotechnol. 2020 Dec;104(23):10203-10215
pubmed: 33064186
Int J Mol Sci. 2021 Mar 14;22(6):
pubmed: 33799405
Int Immunopharmacol. 2018 Apr;57:25-32
pubmed: 29455070
Nat Rev Gastroenterol Hepatol. 2012 Feb 21;9(4):219-30
pubmed: 22349170
Semin Immunopathol. 2015 Jan;37(1):47-55
pubmed: 25420450
Bioeng Transl Med. 2021 Apr 02;6(3):e10219
pubmed: 34589596
Dis Model Mech. 2015 Jan;8(1):1-16
pubmed: 25561744
Cell Host Microbe. 2012 Oct 18;12(4):509-20
pubmed: 22999859
Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):461-478
pubmed: 31123355
Science. 2018 May 25;360(6391):915-918
pubmed: 29798884
Tissue Barriers. 2017 Oct 2;5(4):e1373208
pubmed: 28956703
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
pubmed: 18936492
mSystems. 2019 Jun 11;4(4):
pubmed: 31186335
Front Microbiol. 2017 Jul 11;8:1274
pubmed: 28744268
J Mol Microbiol Biotechnol. 2011;21(3-4):138-46
pubmed: 22286041
Sci Rep. 2018 Jan 17;8(1):1009
pubmed: 29343791
Foods. 2022 Apr 04;11(7):
pubmed: 35407131
Science. 2000 Aug 25;289(5483):1352-5
pubmed: 10958782
Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018
pubmed: 31054246
Curr Opin Pharmacol. 2018 Dec;43:81-86
pubmed: 30218940
Eur J Immunol. 2016 Oct;46(10):2426-2437
pubmed: 27457183
J Biotechnol. 2013 Oct 20;168(2):120-9
pubmed: 23664884
Inflamm Bowel Dis. 2011 Jan;17(1):179-84
pubmed: 20839241
Gut. 2010 Apr;59(4):461-9
pubmed: 19736360
Nat Biotechnol. 2017 Jul;35(7):653-658
pubmed: 28553941
Cancer Gene Ther. 2000 Feb;7(2):269-74
pubmed: 10770636
Inflamm Bowel Dis. 2011 Sep;17(9):1925-35
pubmed: 21830271
Cell Host Microbe. 2012 Aug 16;12(2):139-52
pubmed: 22863420
Front Microbiol. 2017 Feb 01;8:114
pubmed: 28203226
Diagnostics (Basel). 2021 Jun 15;11(6):
pubmed: 34203609
Inflammopharmacology. 2014 Jun;22(3):195-8
pubmed: 24647619
J Med Microbiol. 2016 Feb;65(2):160-168
pubmed: 26567174
J Transl Med. 2018 Mar 20;16(1):71
pubmed: 29554971
Res Microbiol. 2003 Jan-Feb;154(1):59-66
pubmed: 12576161
Front Microbiol. 2017 Jun 09;8:1053
pubmed: 28649237
Gut. 2014 Aug;63(8):1300-12
pubmed: 24082036
PLoS One. 2013 Oct 24;8(10):e76520
pubmed: 24204633
Microbiol Immunol. 2013 Apr;57(4):309-15
pubmed: 23586634
Pilot Feasibility Stud. 2018 Apr 23;4:79
pubmed: 29713493
Mol Ther. 2015 Feb;23(2):278-89
pubmed: 25393372
Nat Microbiol. 2021 May;6(5):563-573
pubmed: 33820962
Arch Microbiol. 2015 Jan;197(1):1-10
pubmed: 25294190
Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14422-7
pubmed: 12381787
Inflamm Bowel Dis. 2018 Feb 15;24(3):558-572
pubmed: 29462379
Cochrane Database Syst Rev. 2020 Mar 4;3:CD005573
pubmed: 32128795
Cell Mol Immunol. 2021 Oct;18(10):2344-2357
pubmed: 34480146
Front Immunol. 2019 Mar 11;10:277
pubmed: 30915065
Gastroenterology. 2004 Aug;127(2):502-13
pubmed: 15300583
Gastroenterol Hepatol Bed Bench. 2019 Spring;12(2):163-168
pubmed: 31191842
Nutr Rev. 2010 Aug;68(8):459-64
pubmed: 20646223
J Extracell Vesicles. 2019 Jun 24;8(1):1632100
pubmed: 31275534
J Mol Microbiol Biotechnol. 2008;14(1-3):48-58
pubmed: 17957110
J Bacteriol. 2007 Apr;189(8):3256-70
pubmed: 17307855
J Dairy Sci. 1990 Oct;73(10):3013-22
pubmed: 2283426
Cell Mol Gastroenterol Hepatol. 2017 Mar 23;4(1):33-46
pubmed: 28560287
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21780-21788
pubmed: 31591215
Pharmaceutics. 2021 Sep 09;13(9):
pubmed: 34575506
Pathogens. 2019 Aug 13;8(3):
pubmed: 31412603
Front Pharmacol. 2021 Apr 27;12:639728
pubmed: 33986673